TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Medically stable persons between age of 18-60~* Available during the trial period and for follow-up~* Able to read, understand, and sign informed consent~* Able to be contacted by telephone for follow-up of adverse events~Exclusion Criteria:~* Use of experimental vaccines within the month prior to study entry, or expected use of experimental or licensed vaccines or blood/blood products during the duration of the study.~* Receipt of immunoglobulin or other blood product within 3 months prior to enrollment~* Receipt of other licensed vaccines within the preceding 4 weeks~* History of a severe reaction following influenza vaccination~* Use of cytotoxic therapy or biologic modifiers in the previous 2 years.~* Plans to receive cytotoxic therapy during the study period.~* Concurrent acute moderate to severe illness. (Vaccination will be deferred until recovery. Subjects with mild illnesses with fever ≤37.8ºC orally may be enrolled).~* History of medical disorder associated with immunosuppression (eg. including HIV-infected individuals, transplant recipients)~* History of chronic lung, cardiac, renal or liver disease, which has required hospitalization in the last year.~* Receipt of any high-dose daily systemic corticosteroids (inhaled steroids are acceptable) within two weeks of study entry. High dose is defined as a dose of 20 mg of prednisone daily or its equivalent. Topical steroids are allowed.~* Failure to give written, informed consent~* History of febrile illness (\>37.8ºC orally) within the past 72 hours (immunization may be deferred).~* Known allergy to eggs or other components of vaccine (i.e., thimerosal)~* History of Guillain-Barré Syndrome (GBS)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Intanza - self-administered (Type: ACTIVE_COMPARATOR): Self-administered intradermal influenza vaccine
- Intanza - nurse-administered (Type: ACTIVE_COMPARATOR): Nurse-administered intradermal influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Follow-up of Fingolimod Phase II Study Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any assessment is performed.~* Randomized in study FTY720D2201 and received at least one dose of study drug.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 2 CFTY720D2201 (NCT02307838) participants (Type: OTHER): CFTY720D2201E2 participants did not receive any protocol specified treatment. The original D2201 study sites, who agreed to participate in this study, were required to locate their participants who were randomized in D2201 and asked them to return for a 10 year assessment, regardless of current treatment status.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with Visceral Leishmaniosis (VL) during the recruitment period that are EITHER treated for VL relapse and have a documented negative test of cure (TOC), OR are treated for primary VL and have a documented CD4 \<200 or WHO stage 4 disease during the recruitment period and have a documented negative TOC~* Patients treated for VL in the past with documented CD4 \<200 or WHO stage 4 disease during the recruitment period AND documented negative TOC after the latest VL treatment and currently asymptomatic OR currently negative diagnostic test (microscopy)~* Patients agreeing to start or continue antiretroviral treatment (first or second line)~* Patients willing to provide written informed consent~Exclusion Criteria:~* Patients with known hypersensitivity to pentamidine~* Patients with known renal failure~* Patients with diabetes mellitus (type I or II)~* Patients unlikely to attend follow-up visits/comply with study requirements~* Pregnant and lactating women~* Any other condition that could increase the risk of toxicity of pentamidine to such an extent outweighing the expected benefit (eg severe cardiac dysfunction).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pentamidine Secondary Prophylaxis (PSP) (Type: EXPERIMENTAL): Patients with co-infection of human immunodeficiency virus (HIV)and visceral leishmaniosis (VL), having being treated for VL, are allocated to pentamidine secondary prophylaxis, to prevent VL relapses. The treatment period is of 12 months, plus an extended treatment period of 0 to 6 months depending on the immunosuppression status, plus 12 months follow-up after the extended treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cesarean delivery~* Meet facility guidelines for postpartum venous thromboembolism (VTE) prophylaxis: Presence of 1 major, or 2 or more moderate, risk factors.~* Major risk factors: history of venous thromboembolism, high risk thrombophilia, BMI ≥40, high risk medical comorbidities (heart disease, sickle cell disease, systemic lupus erythematosus, inflammatory bowel disease), cesarean hysterectomy, nephrotic range proteinuria, or cesarean intrapartum/during labor~* Moderate risk factors: BMI \> 30, multifetal pregnancy, postpartum hemorrhage (\>1L blood loss), tobacco use, non-laboring or elective cesarean, preeclampsia, infection, preterm delivery (\< 37 weeks gestational age), age \> 35 years, low risk thrombophilia, family history of venous thromboembolism, stillbirth, varicose veins, prolonged labor (\> 24 hours)~Exclusion Criteria:~* Contraindication to anticoagulation~* Plan for therapeutic anticoagulation (antepartum or postpartum)~* Known renal dysfunction (Creatinine clearance \< 30 mL/minute)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Weight-based LMWH (Type: EXPERIMENTAL): Participants will receive a weight-based dose of prophylactic enoxaparin.~- For all BMI groups: 0.5mg/kg rounded to the nearest 10mg will be injected subcutaneously every 12 hours
- Fixed LMWH (Type: ACTIVE_COMPARATOR): Participants will receive a fixed dose of prophylactic enoxaparin.~* For BMI \<40: 40mg injected subcutaneously every 24 hours~* For BMI \> or = to 40: 40mg injected subcutaneously every 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Prucalopride in Participants With Chronic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of chronic constipation, defined as on average, 2 or fewer spontaneous bowel movements (SBMs) per week and 1 or more of the following for at least a quarter of the time for the last 3 months, while symptom onset was more than 6 months before the screening visit: in more than 25 percent (%) of BMs, participants had very hard (little balls) and/or hard stools, sensation of incomplete evacuation, straining at defecation (making a bowel movement), sensation of ano-rectal obstruction or blockade, and/or need for digital manipulation to facilitate evacuation~* Participants who were considered as constipated (who never had SBMs)~* Participant's constipation is functional~* Participants with the diagnosis of irritable bowel syndrome (bowel disorder in which there is pain and diarrhea or constipation) with constipation and with no other organic diseases can potentially be included depending on the decision of the investigator~* Female participants must be postmenopausal (for at least 1 year) or surgically sterile or practicing a highly effective method of birth control~Exclusion Criteria:~* Secondary to other diseases/conditions (endocrine disorders, metabolic disorders or neurologic disorders or drug-induced or suspected organic disorders of the large bowel, i.e., obstruction, carcinoma (type of cancer), or inflammatory bowel disease)~* - Participants Using or intending to use disallowed medications that may influence the bowel habit during the study~* Participants with severe (very serious, life threatening) and clinically uncontrolled cardiovascular, liver, or lung disease, neurologic or psychiatric disorders (including active alcohol or drug abuse), cancer (abnormal tissue that grows and spreads in the body until it kills) or acquired immune deficiency syndrome (AIDS: illness that results in decreased ability of the body to protect itself from other illnesses; development of the disease or conditions associated with the disease results from Human Immunodeficiency Virus \[HIV\]), or other gastrointestinal or endocrine disorders~* Participants with impaired renal function, that is, serum creatinine greater than 2 milligram per deciliter (greater than 180 micro mole per liter)~* Participants with clinically significant abnormalities of hematology, urinalysis, or blood chemistry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Prucalopride (Type: EXPERIMENTAL): prucalopride 2- milligram (mg), orally once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo, orally once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Nifedipine Versus Oral Labetalol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years with the abililty to give informed consent~* Intrauterine pregnancy ≥ 32 weeks~* Postpartum~* Persistent postpartum blood pressures ≥ 160/105 on two or more occasions~* Primary obstetrician amenable to starting either study medication in the postpartum period~Exclusion Criteria:~* Use of other oral antihypertensives concomitantly~* Known AV heart block~* HR \<60 or \>120~* Absolute contraindication to nifedipine or labetolol such as allergy~* Significant renal disease (Cr \>1.5 mg/dL)~* Heart failure~* Moderate persistent or severe asthma~* Preexisting diagnosis of chronic hypertension with medical treatment before delivery~* Chronic hypertension

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Labetalol (Type: OTHER): Labetalol 200mg PO BID starting dose
- Nifedipine (Type: OTHER): Nifedpine XL starting at dose 30mg PO daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* Individuals with chronic genotype 3 HCV infection and compensated cirrhosis~* Individuals with or without HIV-1 coinfection~Key Exclusion Criteria:~* History of clinically significant illness or any other medical disorder that may interfere with individual's treatment assessment or compliance with the protocol~* Co-infection with active hepatitis B virus~* Laboratory results outside the acceptable ranges at screening~* Pregnant or nursing female~* Chronic liver disease not caused by HCV~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL FDC for 12 weeks
- SOF/VEL + RBV (Type: EXPERIMENTAL): SOF/VEL FDC + RBV for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Treatment with oral antidiabetic drugs (OADs) for at least three months before trial start at an unchanged dose~* HbA1c: 7.0-10.0%~* Body Mass Index (BMI) no higher than 40.0 kg/m\^2~* For the extension trial only: Completion of the 52 week treatment period in trial NN1250-3579 (NCT00982644)~Exclusion Criteria:~* Treatment with exenatide or liraglutide within the last 3 months before trial start~* Cardiovascular disease within the last 6 months~* Uncontrolled treated/untreated severe hypertension~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures~* Cancer and medical history of cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg OD (Type: EXPERIMENTAL): None
- IGlar OD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-confirmed NHL (DLBCL only for Parts B and C)~* Relapsed or refractory disease following at least 1 prior systemic therapy~* Measurable disease of at least 1.5 cm as documented by CT~* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2~Exclusion Criteria:~* History of another primary invasive malignancy that has not been in remission for at least 3 years~* Current diagnosis of systemic or cutaneous anaplastic large cell lymphoma or mycosis fungoides~* B cell lymphoma previously treated with only single-agent rituximab (for patients receiving brentuximab vedotin only) or corticosteroids as monotherapy~* Known cerebral/meningeal disease

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin+rituximab (Type: EXPERIMENTAL): None
- Brentuximab vedotin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: Exposure to an index case of hepatitis A within 14 days of onset of illness; at least 2 years and no more than 40 years of age at time of study entry; susceptible to hepatitis A; give informed consent or have informed consent given by a responsible parent/guardian -~Exclusion Criteria: history of hepatitis A; prior receipt of hepatitis A vaccine; receipt of immune globulin within 180 days before study entry; evidence of liver disease; receipt of any live virus vaccine within 21 days prior to study entry; moderate or severe intercurrent illness or axillary temperature of 37.5 degrees or higher at time of study entry; various other medical conditions;~-

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin Treatment of Alcohol Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women over age 18 with alcohol dependence~Exclusion Criteria:~* Currently meets Diagnostic and Statistical Manual 4 Text Revision (DSM-IV-TR) criteria for dependence on illicit substances~* Significant medical disorders that will increase potential risk or interfere with study participation~* Women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control~* Treatment with an investigational drug in the last month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gabapentin 900mg daily (Type: EXPERIMENTAL): 900mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
- gabapentin 1800mg daily (Type: EXPERIMENTAL): 1800 mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks
- placebo daily (Type: PLACEBO_COMPARATOR): placebo capsules daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18-80 will be recruited.~* All will have an established radiological diagnosis of bronchiectasis (CT of the chest).~* Patients colonised with Pseudomonas Aeruginosa.~* Able to give informed consent.~Exclusion Criteria:~* Current smokers or ex-smokers of less than 1 year; \>15 pack year history~* Cystic fibrosis~* Active allergic bronchopulmonary aspergillosis~* Active tuberculosis~* Poorly controlled asthma~* Pregnancy or breast feeding~* Known allergy to statins~* Active malignancy~* Chronic liver disease~* Established cardiovascular or cerebrovascular disease~* Statin use in the last year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ATORVASTATIN (Type: ACTIVE_COMPARATOR): Atorvastatin 80mg once daily for 3 months, 1.5 month wash out, then Placebo for 3 months
- PLACEBO (Type: PLACEBO_COMPARATOR): Placebo 3 months, then washout for 1.5 months, then Atorvastatin 80mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. PADIS-PE Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a first episode of idiopathic pulmonary embolism who have been treated during 6 months (Plus 30 days or minus 15 days) using Vitamin K antagonist with a INR between 2 and 3.~Exclusion Criteria:~* Age \< 18~* warfarin hypersensibility~* unwilling or unable to give written informed consent~* distal or proximal deep vein thrombosis~* Pulmonary embolism which was provoked by a reversible major risk factor~* major thrombophilia (protein C, S or antithrombin deficiency, antiphospholipids antibodies, homozygous factor V Leiden)~* previous documented episode of proximal deep vein thrombosis or pulmonary embolism~* other indication for anticoagulant therapy (e.g.:atrial fibrillation, mechanic valve)~* patient on antithrombotic agent in whom antithrombotic agent should be started again after stopping anticoagulation~* pregnancy~* women without contraception~* planned major surgery in the next 18 months~* ongoing cancer or cured cancer in less than 2 years~* serious bleeding risk (e.g.: gastric ulcer)~* platelet count less than 100 Giga/l~* Life expectancy less than 18 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 18 months of active warfarin therapy
- 2 (Type: PLACEBO_COMPARATOR): 18 months of placebo of warfarin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete